Promising Themes Study

Generic Clearance for the Collection of Quantitative Data on Tobacco Products and Communications

2. Promising Themes Adult Consent

Promising Themes Study

OMB: 0910-0810

Document [docx]
Download: docx | pdf

RTI International

Page 0 of 2


YOUNG ADULT INFORMED CONSENT FORM


Sponsor / Study Title:


RTI International / “Promising Themes Study (Unique Minds)”


Principal Investigator:

(Investigator)


Jennifer Duke


Telephone:


919-541-1249 (24 Hour)


Address:

RTI International

3040 Cornwallis Rd

Research Triangle Park, NC 27709


Key Information


You have been asked to take part in a national, online study called Unique Minds. The purpose of this research study is to understand your beliefs about tobacco and marijuana use. RTI International, a non-profit research organization, is surveying 1,700 youth and young adults across the country in this wave of the study. The self-administered online survey will be used to gather your perceptions about various tobacco and marijuana products. It will take about 20 minutes for you to complete this survey. If you complete the survey, you will receive a token of appreciation for your time in the form of a $5 digital Amazon gift card. There will be no charge to you for your participation in this study.


You will not be harmed by being in this study. There is a small chance that you might feel embarrassed or upset by the questions asked in the survey. However, you can respond “prefer not to answer” to any question and may drop out of the survey at any time for any reason. We recommend that you take the survey in a place that is private, to reduce the chance of someone else seeing your responses. Please do not take the survey while driving, and please be prepared to take the survey in one sitting.


It is your choice to take part in this study. There are no direct benefits to you from taking this survey. However, you will be contributing to important research related to tobacco. Your answers will help the U.S. Food and Drug Administration (FDA) develop new campaign messages for future FDA media campaigns.


If you are interested in learning more about this study, please continue to read below.


You will enter your responses to the questions directly into the self-administered online survey. If you do not enter any responses for 60 minutes, you will be automatically logged out. This is to protect your privacy, so nobody will be able to see any survey responses on your screen. For the same reason, it is not possible to move backward through the survey. You will not be allowed to re-enter the survey. We will not ask you your name. Some personal information, like your email address and age, will be gathered. Your answers will be labeled with a number instead of your name. This makes it so only study staff will know these are your answers. Your answers will not be shared with your parent or legal guardian. You may choose not to participate, or you may stop taking the survey at any time at any time without penalty.


You will receive the incentive if you complete the survey, even if you select “prefer not to answer” to every survey question. You can respond “prefer not to answer” to any question and may drop out of the survey at any time for any reason. However, if you drop out of the survey before reaching the last item, you will not receive an incentive. You will be allowed to complete additional Unique Minds surveys after 6 months. You will need to re-consent to future Unique Minds surveys and if you qualify, you are entitled to compensation for each survey completed.


The study staff understands that the security of online transmissions is not guaranteed due to the risk of interception by third parties, or the possibility of monitoring software installed on research participants’ electronic devices. Your identity will not be known in the results of the study. Everything you share will be kept private to the extent allowed by law. Only the authorized study staff will have access to your responses. We are only interested in the combined responses from everyone who is selected to participate, not just one person’s answers. Data will not be analyzed or reported in such a way that it will be possible to identify any individual participant. We will not share any information you give us with anyone outside the FDA and RTI study staff. However, your answers could be used for future research studies or distributed to another investigator for future research studies without additional informed consent. If that happens, all identifiable private information will be removed before your answers are shared.


The investigator can stop your participation at any time without your consent for the following reasons:


  • If you fail to follow directions for participating in the study;

  • If it is discovered that you do not meet the study requirements;

  • If the study is canceled; or

  • For administrative reasons.


This study is for research purposes only. The only alternative is to not participate in this study. Any new important information that is discovered during the study and which may influence your willingness to continue participation in the study will be provided to you.


Whom to Contact About This Study


During the study, if you have questions, concerns or complaints about the study, please contact the investigator at the telephone number listed on the first page of this consent document.


An institutional review board (IRB) is an independent committee established to help protect the rights of research participants. If you have any questions about your rights as a research participant, and/or concerns or complaints regarding this research study, contact:


  • By mail:

Study Subject Adviser

Advarra IRB

6100 Merriweather Dr., Suite 600

Columbia, MD 21044


Please reference the following number when contacting the Study Subject Adviser: Pro00056348.


Certificate of Confidentiality


This study is covered by a special protection called a Certificate of Confidentiality (CoC). This special protection requires that study staff involved in this study protect your privacy. This means study staff generally cannot provide any other information that could identify you to anyone who is not connected with the study. Study staff cannot share this information in court or during other legal proceedings, unless you agree, even if there is a court order for the information. However, in other settings, study staff may share study information that could identify you if:


  • You agree to share information (for example, to get medical treatment);

  • The study information is used for other scientific research that follows federal law;

  • The FDA, which is paying for the study, needs information to check how their money is being spent; or

  • A law requires sharing information (for example, when study staff must report to FDA, or if study staff hear threats of harm to yourself or others or reports of child abuse).


The Certificate of Confidentiality does not prevent you from sharing any personal information or information about your involvement in this study with others. For example, you can share that you are in this study or your history of tobacco use.


I understand the study purpose and process.


Do you agree to participate in this survey?


Yes, I agree to participate in this survey.


No, I do NOT agree to participate in this survey.



OMB No: 0910-0810 Expiration Date: 12/31/2024


Paperwork Reduction Act Statement: According to the Paperwork Reduction Act of 1995, an agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a valid OMB control number. The valid OMB control number for this information collection is 0910-0810. The time required to complete this information collection is estimated to average 2 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspects of this collection of information, including suggestions for reducing burden to PRASTAFF@fda.hhs.gov.


Jennifer Duke

Advarra IRB Approved Version 14 Sep 2021



File Typeapplication/vnd.openxmlformats-officedocument.wordprocessingml.document
AuthorChapman, LeTonya
File Modified0000-00-00
File Created2023-08-18

© 2024 OMB.report | Privacy Policy